Academisch Ziekenhuis Leiden

Johannes Theodorus Den Dunnen

Garrit-Jan Boudewijn Van Ommen

Judith Christina Theodora Van Deutekom

Annemieke Aartsma-Rus

Peter Abraham Christiaan 't Hoen

Judith C T Van Deutekom

Petronella Johanna Elisabeth Sterrenburg

Garrit Jan Boudewijn Van Ommen

Peter Abraham Christiaan 'T Hoen

Petronella Johanna Elisabeth Sterrenberg

The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides.

Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure

The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.

The present invention provides means and methods for alleviating genetic disease. A genetic defect that has a phenotype in differentiated cells can lead to defects in precursor cells thereof. These so-called secondary defects contribute to the overall disease of the individual. In the present invention, genetic intervention with the aim to alleviate symptoms of genetic disease is directed toward the primary genetic defect in the differentiated cell and the secondary defect in the precursor cell.

Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly or abnormally expressed gene

The present invention provides a method for at least in part decreasing the production of an aberrant protein in a cell, the cell comprising pre-mRNA comprising exons coding for the protein, by inducing so-called exon skipping in the cell. Exon-skipping results in mature MRNA that does not contain the skipped exon, which leads to an altered product of the exon codes for amino acids. Exon skipping is performed by providing a cell with an agent capable of specifically inhibiting an exon inclusion signal, for instance, an exon recognition sequence, of the exon. The exon inclusion signal can be interfered with by a nucleic acid comprising complementarity to a part of the exon. The nucleic acid, which is also herewith provided, can be used for the preparation of a medicament, for instance, for the treatment of an inherited disease.

Growing community of inventors

Rotterdam, Netherlands

Johannes Theodorus Den Dunnen